content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on December 12, 2024&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>UNDER</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>ADIAL PHARMACEUTICALS, INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>(Exact name of registrant as specified in its
  charter)</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>&nbsp;</I></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="width: 2%; text-align: center; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>82-3074668</B></FONT></TD></TR>
    <TR>
      <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State or other jurisdiction of<BR>
  incorporation or organization)</I></FONT></TD>
      <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>(I.R.S. Employer No.)</I></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>Identification Number)</I></P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>4870 Sadler Road, Suite 300<BR>
  Glen Allen, Virginia 23060<BR>
  (804) 487-8196</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>(Address, including ZIP code, and telephone
  number, including area code, of registrant&rsquo;s principal executive office)</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>ADIAL PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE
  PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>(Full title of the Plan)</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Cary J. Claiborne</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>President and Chief Executive Officer</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Adial Pharmaceuticals, Inc.<BR>
  4870 Sadler Road, Suite 300<BR>
  Glen Allen, Virginia 23060<BR>
  (804) 487-8196</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>(Name, address and telephone number of agent
  for service)</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>with copies to:</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Leslie Marlow, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Patrick J. Egan, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Hank Gracin, Esq</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Blank Rome LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>1271 Avenue of the Americas</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>New York, New York 10020</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>(212) 885-5000</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>(Name, address and telephone number)</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; &ldquo;smaller reporting company&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &nbsp;&nbsp;&#9744;</FONT></TD>
      <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &nbsp;&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &nbsp;&nbsp;&nbsp;&nbsp;&#9746;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company &nbsp;&#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company &nbsp;&#9744;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B></B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B></B></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Adial Pharmaceuticals, Inc.
  (the &ldquo;Registrant&rdquo; or the &ldquo;Company&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
  its Registration Statement on Form S-8 (Registration No. 333-226884) on August 16, 2018 (the &ldquo;2018 Registration Statement&rdquo;)
  for the purpose of registering under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), 1,750,000 shares (70,000
  shares post-Reverse Stock Split (as defined below)) of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), to be
  offered and sold under the Registrant&rsquo;s 2017 Equity Incentive Plan (hereinafter referred to as the &ldquo;Plan&rdquo;).&nbsp;&nbsp;Pursuant
  to General Instruction E to Form S-8, the contents of the 2018 Registration Statement are incorporated into this Registration Statement
  by reference.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
  Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-233760) on September 13, 2019 (the
  &ldquo;2019 Registration Statement&rdquo;) pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for
  the purpose of registering under the Securities Act an additional 1,750,000 shares </FONT>(70,000 shares post-Reverse Stock Split<FONT STYLE="background-color: white">)
  of Common Stock to be offered and sold under the Plan.&nbsp;&nbsp;These additional shares of Common Stock were added pursuant to the adoption
  of Amendment No. 1 to the Plan. &nbsp;Pursuant to General Instruction E to Form S-8, the contents of the 2019 Registration Statement are
  incorporated into this Registration Statement by reference.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
  Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-248759) on September 11, 2020 (the
  &ldquo;2020 Registration Statement&rdquo;) pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for
  the purpose of registering under the Securities Act an additional 2,000,000 shares </FONT>(80,000 shares post-Reverse Stock Split<FONT STYLE="background-color: white">)
  of Common Stock to be offered and sold under the Plan.&nbsp;&nbsp;These additional shares of Common Stock were added pursuant to the adoption
  of Amendment No. 2 to the Plan. &nbsp;Pursuant to General Instruction E to Form S-8, the contents of the 2020 Registration Statement are
  incorporated into this Registration Statement by reference.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Registrant also filed
  with the Commission its Registration Statement on Form S-8 (Registration No. 333-260304) on October 15, 2021 (the &ldquo;2021 Registration
  Statement&rdquo;) to register an additional 2,000,000 shares (80,000 shares post-Reverse Stock Split<FONT STYLE="background-color: white">)
  </FONT>of Common Stock that were added to the Plan by a vote of the Registrant&rsquo;s stockholders at the Registrant&rsquo;s 2021 Annual
  Meeting of Stockholders, which was held on September 27, 2021. <FONT STYLE="background-color: white">These additional shares of Common
  Stock were added pursuant to the adoption of Amendment No. 3 to the Plan. The aggregate number of shares of Common Stock issuable under
  the Plan, as amended, after the adoption of Amendment No. 3 to the Plan, was 7,500,000 shares </FONT>(300,000 shares post-Reverse Stock
  Split<FONT STYLE="background-color: white">). &nbsp;Pursuant to General Instruction E to Form S-8, the contents of the 2021 Registration
  Statement are incorporated into this Registration Statement by reference.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Registrant also filed
  with the Commission its Registration Statement on Form S-8 (Registration No. 333-267972) on October 21, 2022 (the &ldquo;2022 Registration
  Statement&rdquo;) to register an additional 2,000,000 shares (80,000 shares post-Reverse Stock Split<FONT STYLE="background-color: white">)
  </FONT>of Common Stock that were added to the Plan by a vote of the Registrant&rsquo;s stockholders at the Registrant&rsquo;s 2022 Annual
  Meeting of Stockholders, which was held on October 13, 2022. <FONT STYLE="background-color: white">These additional shares of Common Stock
  were added pursuant to the adoption of Amendment No. 4 to the Plan. The aggregate number of shares of Common Stock issuable under the
  Plan, as amended, after the adoption of Amendment No. 4 to the Plan, was 9,500,000 shares </FONT>(380,000 shares post-Reverse Stock Split<FONT STYLE="background-color: white">).
  &nbsp;Pursuant to General Instruction E to Form S-8, the contents of the 2022 Registration Statement are incorporated into this Registration
  Statement by reference.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">On August 4, 2023, the Registrant
  effected a reverse stock split of its outstanding shares of Common Stock at a ratio of 1-for-25 (the &ldquo;Reverse Stock Split&rdquo;),
  which reduced the number of shares of Common Stock reserved under the Plan to 380,000.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Registrant also filed
  with the Commission a Registration Statement on Form S-8 (Registration No. 333-276003) on December 12, 2023 (the &ldquo;2023 Registration
  Statement&rdquo;) to register an additional 120,000 shares (post-Reverse Stock Split) of Common Stock that were added to the Plan by a
  vote of the Registrant&rsquo;s Board of Directors and the Registrant&rsquo;s stockholders at the Registrant&rsquo;s 2023 Annual Meeting
  of Stockholders, which was held on November 2, 2023. <FONT STYLE="background-color: white">These additional 120,000 shares of Common Stock
  were added pursuant to the adoption of Amendment No. 5 to the Plan. The aggregate number of shares of Common Stock that may be issued
  under the Plan, as amended, after the adoption of Amendment No. 5 to the Plan, is 500,000 shares. &nbsp;Pursuant to General Instruction
  E to Form S-8, the contents of the 2023 Registration Statement are incorporated into this Registration Statement by reference.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Registrant is filing this
  Registration Statement on Form S-8 (the &ldquo;Registration Statement&rdquo;) to register an additional 1,500,000 shares of Common Stock
  that were added to the Plan by a vote of the Registrant&rsquo;s Board of Directors and the Registrant&rsquo;s stockholders at the Registrant&rsquo;s
  2024 Annual Meeting of Stockholders, which was held on November 12, 2024.&nbsp;These additional 1,500,000 shares of Common Stock were
  added pursuant to the adoption of Amendment No. 6 to the Plan. The aggregate number of shares of Common Stock that may be issued under
  the Plan, as amended, after the adoption of Amendment No. 6 to the Plan, is 2,000,000 shares. &nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The information specified
  in Item 1 and Item 2 of Part I of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions
  of Rule 428 under the Securities Act, and the introductory note to Part I of Form S-8. The documents containing the information specified
  in Part I will be delivered to the participants in the Plan as required by Rule 428(b)(1). Such documents and the documents incorporated
  by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a
  prospectus that meets the requirements of Section 10(a) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Item 3. Incorporation of Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Securities and Exchange
  Commission (the &ldquo;Commission&rdquo;) allows the Registrant to &ldquo;incorporate by reference&rdquo; the information it files with
  it which means that it can disclose important information to you by referring you to those documents instead of having to repeat the information
  in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that
  the Registrant files with the Commission will automatically update and supersede this information. The Registrant incorporates by reference
  the documents listed below and any future filings made with the Commission (Commission <FONT STYLE="background-color: white">File No.
  001-38323) </FONT>under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus and the termination
  of the offering:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Registrant&rsquo;s Annual Report on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024028701/ea0202434-10k_adial.htm">Form 10-K</A>&nbsp;for the year ended December 31, 2023 filed with the Commission on April 1, 2024;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the Registrant&rsquo;s </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024043023/ea0205885-10q_adialpharma.htm">Form 10-Q</A> for the quarter ended March 31, 2024 filed with <FONT STYLE="background-color: white">the Commission</FONT> on May 14, 2024, the Registrant&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024068262/ea0210867-10q_adial.htm">Form 10-Q</A> for the quarter ended June 30, 2024 filed with the Commission on August 13, 2024, and the Registrant&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024097519/ea0220287-10q_adial.htm">Form 10-Q</A> for the quarter ended September 30, 2024 filed with the Commission on November 13, 2024;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the Registrant&rsquo;s </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Reports on Form 8-K filed with <FONT STYLE="background-color: white">the Commission</FONT> on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024003750/ea191680-8k_adialpharma.htm">January 16, 2024</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024004505/ea191817-8k_adialpharma.htm">January 18, 2024</A>&nbsp;(other than as indicated therein), <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024020440/ea0201235-8k_adialpharma.htm">March 6, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024033471/ea020390801-8k_adialpharm.htm">April 16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024034186/ea0203748-8k_adial.htm">April 18, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024036613/ea0204623-8k_adialphar.htm">April 26, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024094344/ea0219983-8k_adial.htm">November 5, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024096796/ea0220869-8k_adial.htm">November 12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024099633/ea022169101-8k_adialpharm.htm">November 18, 2024</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024106554/ea0223975-8k_adialpharm.htm">December 6, 2024</A>; and&nbsp;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the Registrant&rsquo;s </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024082805/ea0212489-01.htm">Schedule 14A</A> filed with <FONT STYLE="background-color: white">the Commission</FONT> on September 27, 2024; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the description of the Registrant&rsquo;s Common Stock set forth in (i) the Registrant&rsquo;s registration statement on</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017013072/f8a12b110617_adialpharma.htm">8-A12B</A><FONT STYLE="background-color: white">, filed with the Commission on December 11, 2017, as amended by the registration statement on Form <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390018009518/f8a12b070618a1_adialphar.htm">8-A12B/A</A> filed with the Commission on July 23, 2018, and (ii) </FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021017009/f10k2020ex4-19_adialpharmac.htm">Exhibit 4.17</A><FONT STYLE="background-color: white">&mdash;Description of Securities to the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Commission on April 1, 2024.</FONT></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">All reports and other documents
  subsequently filed by the Company pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed to be incorporated
  by reference in this Registration Statement and to be a part of this Registration Statement from the respective date of filing of each
  of those reports or documents until the filing of a post-effective amendment to this Registration Statement which indicates either that
  all securities offered by this Registration Statement have been sold or which deregisters all of the securities under this Registration
  Statement then remaining unsold.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Any statement contained in
  this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall
  be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration
  Statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration
  Statement modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or
  superseded, to constitute a part of this Registration Statement.&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Item 4. Description of Securities.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The class of securities to
  be offered is registered under Section 12 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Item&nbsp;5. Interests of Named Experts and Counsel.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Item&nbsp;6. Indemnification of Directors and Officers.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Registrant is incorporated
  under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may
  indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding,
  whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the
  fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such
  corporation as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including
  attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection
  with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be
  in or not opposed to the corporation&rsquo;s best interests and, with respect to any criminal action or proceeding, had no reasonable
  cause to believe that his or her conduct was illegal except that no indemnification is permitted without judicial approval if the officer
  or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the
  defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys&rsquo; fees)
  actually and reasonably incurred.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Registrant&rsquo;s certificate
  of incorporation and bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware
  General Corporation Law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Section 102(b)(7) of the Delaware
  General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall
  not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except
  for liability for any:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transaction from which the director derives an improper personal benefit;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful payment of dividends or redemption of shares; or</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach of a director&rsquo;s duty of loyalty to the corporation or its stockholders.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Registrant&rsquo;s certificate
  of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding
  in advance of its final disposition shall be paid by the Registrant upon delivery to it of an undertaking, by or on behalf of such director
  or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be
  indemnified by the Registrant.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Section 174 of the Delaware
  General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of
  dividends or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the
  unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered
  in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent
  director receives notice of the unlawful acts.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As permitted by the Delaware
  General Corporation Law, the Registrant has entered into indemnity agreements with each of its directors and executive officers, that
  require the Registrant to indemnify such persons against any and all costs and expenses (including attorneys&rsquo;, witness or other
  professional fees) actually and reasonably incurred by such persons in connection with any action, suit or proceeding (including derivative
  actions), whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was
  a director or officer or is or was acting or serving as an officer, director, employee or agent of the Registrant or any of its affiliated
  enterprises. Under these agreements, the Registrant is not required to provide indemnification for certain matters, including:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnification beyond that permitted by the Delaware General Corporation Law;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnification for any proceeding with respect to the unlawful payment of remuneration to the director or officer;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnification for certain proceedings involving a final judgment that the director or officer is required to disgorge profits from the purchase or sale of the Registrant&rsquo;s stock;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnification for proceedings involving a final judgment that the director&rsquo;s or officer&rsquo;s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct or a breach of his or her duty of loyalty, but only to the extent of such specific determination;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnification for proceedings or claims brought by an officer or director against us or any of the Registrant&rsquo;s directors, officers, employees or agents, except for claims to establish a right of indemnification or proceedings or claims approved by the Registrant&rsquo;s board of directors or required by law;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnification for settlements the director or officer enters into without the Registrant&rsquo;s consent; or</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnification in violation of any undertaking required by the Securities Act or in any registration statement filed by the Registrant.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The indemnification agreements
  also set forth certain procedures that will apply in the event of a claim for indemnification thereunder.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Registrant has an insurance
  policy in place that covers its officers and directors with respect to certain liabilities, including liabilities arising under the Securities
  Act or otherwise.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Item 7. Exemption from Registration Claimed.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>EXHIBIT
  INDEX</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: top; width: 8%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
      <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 91%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017010930/fs12017a2ex3-3_adial.htm">Certificate of Incorporation of Adial Pharmaceuticals, Inc. (1)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390023063213/ea182870ex3-1_adialpharm.htm">Certificate of Amendment to Certificate of Incorporation of Adial Pharmaceuticals, Inc. (2)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390022015562/f10k2021ex3-3_adialpharma.htm">Amended and Restated Bylaws of Adial Pharmaceuticals, Inc. (3)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390018011309/fs82018ex4-1_adialpharma.htm">Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (4)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390019018002/fs82019ex4-2_adialpharma.htm">Amendment No. 1 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (5)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017009468/fs12017ex4-12_adialpharma.htm">Form of Stock Option Grant Notice, Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) and Notice of Exercise under the 2017 Equity Incentive Plan (6)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390020026280/ea126600ex4-4_adialpharma.htm">Amendment No. 2 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (7)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021050629/ea147995ex10-1_adial.htm">Amendment No. 3 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (8)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390022063864/ea167124ex10-1_adialpharm.htm">Amendment No. 4 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (9)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390023083634/ea187742ex10-1_adialpharma.htm">Amendment No. 5 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (10)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390024096796/ea022086901ex10-1_adial.htm">Amendment No. 6 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (11)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022439601ex5-1_adial.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Blank Rome LLP (12)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022439601ex23-1_adial.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Marcum, LLP, Independent Registered Public Accounting Firm (12)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022439601ex5-1_adial.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Blank Rome LLP (contained in Exhibit 5.1) (12)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#POW_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on the signature page of this registration statement) (12)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022439601ex-fee_adial.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table (12)</FONT></A></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Form S-1, as amended (File No. 333-220368), filed with the Securities and Exchange Commission on October 25, 2017.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Form 8-K (File No. 001-38323) filed with the Securities and Exchange Commission on August 4, 2023.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Annual Report on Form 10-K (File No. <FONT STYLE="background-color: white">001-38323</FONT>) filed with the Securities and Exchange Commission March 28, 2022.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Form S-8 (File No. 333-226884) filed with the Securities and Exchange Commission on August 16, 2018.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Form S-8 (File No. 333-233760) filed with the Securities and Exchange Commission September 13, 2019.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Form S-1, as amended (File No. 333-220368), filed with the Securities and Exchange Commission on September 7, 2017.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Form S-8 (File No. 333-248759) filed with the Securities and Exchange Commission September 11, 2020.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Current Report on Form 8-K (File No. <FONT STYLE="background-color: white">001-38323</FONT>) filed with the Securities and Exchange Commission September 29, 2021.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Current Report on Form 8-K (File No. <FONT STYLE="background-color: white">001-38323</FONT>) filed with the Securities and Exchange Commission October 13, 2022.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(10)</TD><TD STYLE="text-align: justify">Incorporated by reference to the Registrant&rsquo;s Current
  Report on Form 8-K (File No. 001-38323) filed with the Securities and Exchange Commission November 6, 2023.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(11)</TD><TD STYLE="text-align: justify">Incorporated by reference to the Registrant&rsquo;s Current
  Report on Form 8-K (File No. 001-38323) filed with the Securities and Exchange Commission November 12, 2024.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(12)</TD><TD STYLE="text-align: justify">Filed herewith.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Item&nbsp;9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">(a) The Registrant hereby
  undertakes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">(1)
  To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">(i)
  To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">(ii)
  To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
  Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
  offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
  may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
  and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
  Fee&rdquo; table in the Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">(iii)
  To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or
  any material change to such information in the registration statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><I>Provided, however</I>,
  that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment
  by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or
  Section&nbsp;15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">(2)
  That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
  a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
  to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">(3)
  To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">(b) The undersigned registrant
  hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual
  report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit
  plan&rsquo;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement
  shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
  that time shall be deemed to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">(h) Insofar as indemnification
  for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
  to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification
  is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
  person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
  settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
  public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in Charlottesville, Virginia, on the 12<SUP>th</SUP> day of December, 2024.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADIAL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="width: 35%">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cary J. Claiborne</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cary J. Claiborne</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B><A NAME="POW_001"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Each of the undersigned, whose
  signature appears below, hereby constitutes and appoints each of Cary J. Claiborne and Vinay Shah, act singly, as his true and lawful
  attorney-in-fact and agent, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all
  capacities, to sign any or all amendments to this Registration Statement, whether pre-effective or post-effective, and to file the same
  with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
  attorney-in-fact and agent, or his substitute full power and authority to do and perform each and every act and thing necessary or appropriate
  to be done with respect to this Registration Statement or any amendments hereto in the premises, as fully to all intents and purposes
  as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes,
  or any of them, may lawfully do or cause to be done by virtue thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the
  date indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="width: 28%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cary J. Claiborne</FONT></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer and Member of the</FONT></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 12, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cary J. Claiborne</FONT></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board of Directors</FONT></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Vinay Shah</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 12, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vinay Shah</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ J. Kermit Anderson</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 12, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Kermit Anderson</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robertson H. Gilliland</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 12, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robertson H. Gilliland</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tony Goodman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 12, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tony Goodman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">/s/ James W. Newman, Jr.</P></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 12, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James W. Newman, Jr.</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kevin Schuyler, CFA</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 12, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin Schuyler, CFA</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-6</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0224396-s8_adialpharma.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 95556}]
metadata_filer: {"company-data": {"conformed-name": "ADIAL PHARMACEUTICALS, INC.", "cik": "0001513525", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "800667150", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-283756", "film-number": "241544850"}, "business-address": {"street1": "1180 SEMINOLE TRAIL", "street2": "SUITE 495", "city": "CHARLOTTESVILLE", "state": "VA", "zip": "22901", "phone": "434-422-9800"}, "mail-address": {"street1": "1180 SEMINOLE TRAIL", "street2": "SUITE 495", "city": "CHARLOTTESVILLE", "state": "VA", "zip": "22901"}, "former-company": [{"former-conformed-name": "ADial Pharmaceuticals, L.L.C.", "date-changed": "20170515"}, {"former-conformed-name": "Adial Pharmaceuticals, L.L.C.", "date-changed": "20110218"}]}
text: As filed with the Securities and Exchange Commission
  on December 12, 2024
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  ADIAL PHARMACEUTICALS, INC.
  (Exact name of registrant as specified in its
  charter)
  Delaware
  82-3074668
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer No.)
  Identification Number)
  4870 Sadler Road, Suite 300
  Glen Allen, Virginia 23060
  (804) 487-8196
  (Address, including ZIP code, and telephone
  number, including area code, of registrant's principal executive office)
  ADIAL PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE
  PLAN
  (Full title of the Plan)
  Cary J. Claiborne
  President and Chief Executive Officer
  Adial Pharmaceuticals, Inc.
  4870 Sadler Road, Suite 300
  Glen Allen, Virginia 23060
  (804) 487-8196
  (Name, address and telephone number of agent
  for service)
  with copies to:
  Leslie Marlow, Esq.
  Patrick J. Egan, Esq.
  Hank Gracin, Esq
  Blank Rome LLP
  1271 Avenue of the Americas
  New York, New York 10020
  (212) 885-5000
  (Name, address and telephone number)
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer" "smaller reporting company"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act:
  Large accelerated filer   ☐
  Accelerated filer  ☐
  Non-accelerated filer     ☒
  Smaller reporting company  ☒
  Emerging growth company  ☐
  If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  EXPLANATORY NOTE
  Adial Pharmaceuticals, Inc.
  (the "Registrant" or the "Company") filed with the Securities and Exchange Commission (the "Commission")
  its Registration Statement on Form S-8 (Registration No. 333-226884) on August 16, 2018 (the "2018 Registration Statement")
  for the purpose of registering under the Securities Act of 1933, as amended (the "Securities Act"), 1,750,000 shares (70,000
  shares post-Reverse Stock Split (as defined below)) of common stock, par value $0.001 per share (the "Common Stock"), to be
  offered and sold under the Registrant's 2017 Equity Incentive Plan (hereinafter referred to as the "Plan").  Pursuant
  to General Instruction E to Form S-8, the contents of the 2018 Registration Statement are incorporated into this Registration Statement
  by reference.
  The
  Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-233760) on September 13, 2019 (the
  "2019 Registration Statement") pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for
  the purpose of registering under the Securities Act an additional 1,750,000 shares
  (70,000 shares post-Reverse Stock Split
  )
  of Common Stock to be offered and sold under the Plan.  These additional shares of Common Stock were added pursuant to the adoption
  of Amendment No. 1 to the Plan.  Pursuant to General Instruction E to Form S-8, the contents of the 2019 Registration Statement are
  incorporated into this Registration Statement by reference.
  The
  Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-248759) on September 11, 2020 (the
  "2020 Registration Statement") pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for
  the purpose of registering under the Securities Act an additional 2,000,000 shares
  (80,000 shares post-Reverse Stock Split
  )
  of Common Stock to be offered and sold under the Plan.  These additional shares of Common Stock were added pursuant to the adoption
  of Amendment No. 2 to the Plan.  Pursuant to General Instruction E to Form S-8, the contents of the 2020 Registration Statement are
  incorporated into this Registration Statement by reference.
  The Registrant also filed
  with the Commission its Registration Statement on Form S-8 (Registration No. 333-260304) on October 15, 2021 (the "2021 Registration
  Statement") to register an additional 2,000,000 shares (80,000 shares post-Reverse Stock Split
  )
  of Common Stock that were added to the Plan by a vote of the Registrant's stockholders at the Registrant's 2021 Annual
  Meeting of Stockholders, which was held on September 27, 2021.
  These additional shares of Common
  Stock were added pursuant to the adoption of Amendment No. 3 to the Plan. The aggregate number of shares of Common Stock issuable under
  the Plan, as amended, after the adoption of Amendment No. 3 to the Plan, was 7,500,000 shares
  (300,000 shares post-Reverse Stock
  Split
  ).  Pursuant to General Instruction E to Form S-8, the contents of the 2021 Registration
  Statement are incorporated into this Registration Statement by reference.
  The Registrant also filed
  with the Commission its Registration Statement on Form S-8 (Registration No. 333-267972) on October 21, 2022 (the "2022 Registration
  Statement") to register an additional 2,000,000 shares (80,000 shares post-Reverse Stock Split
  )
  of Common Stock that were added to the Plan by a vote of the Registrant's stockholders at the Registrant's 2022 Annual
  Meeting of Stockholders, which was held on October 13, 2022.
  These additional shares of Common Stock
  were added pursuant to the adoption of Amendment No. 4 to the Plan. The aggregate number of shares of Common Stock issuable under the
  Plan, as amended, after the adoption of Amendment No. 4 to the Plan, was 9,500,000 shares
  (380,000 shares post-Reverse Stock Split
  ).
   Pursuant to General Instruction E to Form S-8, the contents of the 2022 Registration Statement are incorporated into this Registration
  Statement by reference.
  On August 4, 2023, the Registrant
  effected a reverse stock split of its outstanding shares of Common Stock at a ratio of 1-for-25 (the "Reverse Stock Split"),
  which reduced the number of shares of Common Stock reserved under the Plan to 380,000.
  The Registrant also filed
  with the Commission a Registration Statement on Form S-8 (Registration No. 333-276003) on December 12, 2023 (the "2023 Registration
  Statement") to register an additional 120,000 shares (post-Reverse Stock Split) of Common Stock that were added to the Plan by a
  vote of the Registrant's Board of Directors and the Registrant's stockholders at the Registrant's 2023 Annual Meeting
  of Stockholders, which was held on November 2, 2023.
  These additional 120,000 shares of Common Stock
  were added pursuant to the adoption of Amendment No. 5 to the Plan. The aggregate number of shares of Common Stock that may be issued
  under the Plan, as amended, after the adoption of Amendment No. 5 to the Plan, is 500,000 shares.  Pursuant to General Instruction
  E to Form S-8, the contents of the 2023 Registration Statement are incorporated into this Registration Statement by reference.
  The Registrant is filing this
  Registration Statement on Form S-8 (the "Registration Statement") to register an additional 1,500,000 shares of Common Stock
  that were added to the Plan by a vote of the Registrant's Board of Directors and the Registrant's stockholders at the Registrant's
  2024 Annual Meeting of Stockholders, which was held on November 12, 2024. These additional 1,500,000 shares of Common Stock were
  added pursuant to the adoption of Amendment No. 6 to the Plan. The aggregate number of shares of Common Stock that may be issued under
  the Plan, as amended, after the adoption of Amendment No. 6 to the Plan, is 2,000,000 shares.
  i
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  The information specified
  in Item 1 and Item 2 of Part I of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions
  of Rule 428 under the Securities Act, and the introductory note to Part I of Form S-8. The documents containing the information specified
  in Part I will be delivered to the participants in the Plan as required by Rule 428(b)(1). Such documents and the documents incorporated
  by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a
  prospectus that meets the requirements of Section 10(a) of the Securities Act.
  1
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  The Securities and Exchange
  Commission (the "Commission") allows the Registrant to "incorporate by reference" the information it files with
  it which means that it can disclose important information to you by referring you to those documents instead of having to repeat the information
  in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that
  the Registrant files with the Commission will automatically update and supersede this information. The Registrant incorporates by reference
  the documents listed below and any future filings made with the Commission (Commission
  File No.
  001-38323)
  under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus and the termination
  of the offering:
  ●
  the Registrant's Annual Report on
  Form 10-K
  for the year ended December 31, 2023 filed with the Commission on April 1, 2024;
  ●
  the Registrant's
  Quarterly Report on
  Form 10-Q
  for the quarter ended March 31, 2024 filed with
  the Commission
  on May 14, 2024, the Registrant's Quarterly Report on
  Form 10-Q
  for the quarter ended June 30, 2024 filed with the Commission on August 13, 2024, and the Registrant's Quarterly Report on
  Form 10-Q
  for the quarter ended September 30, 2024 filed with the Commission on November 13, 2024;
  ●
  the Registrant's
  Current Reports on Form 8-K filed with
  the Commission
  on
  January 16, 2024
  ,
  January 18, 2024
  (other than as indicated therein),
  March 6, 2024
  ,
  April 16, 2024
  ,
  April 18, 2024
  ,
  April 26, 2024
  ,
  November 5, 2024
  ,
  November 12, 2024
  ,
  November 18, 2024
  , and
  December 6, 2024
  ; and
  ●
  the Registrant's
  Definitive Proxy Statement on
  Schedule 14A
  filed with
  the Commission
  on September 27, 2024; and
  ●
  the description of the Registrant's Common Stock set forth in (i) the Registrant's registration statement on
  Form
  8-A12B
  , filed with the Commission on December 11, 2017, as amended by the registration statement on Form
  8-A12B/A
  filed with the Commission on July 23, 2018, and (ii)
  Exhibit 4.17
  —Description of Securities to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Commission on April 1, 2024.
  All reports and other documents
  subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed to be incorporated
  by reference in this Registration Statement and to be a part of this Registration Statement from the respective date of filing of each
  of those reports or documents until the filing of a post-effective amendment to this Registration Statement which indicates either that
  all securities offered by this Registration Statement have been sold or which deregisters all of the securities under this Registration
  Statement then remaining unsold.
  Any statement contained in
  this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall
  be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration
  Statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration
  Statement modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or
  superseded, to constitute a part of this Registration Statement.
  II-
  1
  Item 4. Description of Securities.
  The class of securities to
  be offered is registered under Section 12 of the Exchange Act.
  Item 5. Interests of Named Experts and Counsel.
  Not applicable.
  Item 6. Indemnification of Directors and Officers.
  The Registrant is incorporated
  under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may
  indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding,
  whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the
  fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such
  corporation as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including
  attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection
  with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be
  in or not opposed to the corporation's best interests and, with respect to any criminal action or proceeding, had no reasonable
  cause to believe that his or her conduct was illegal except that no indemnification is permitted without judicial approval if the officer
  or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the
  defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys' fees)
  actually and reasonably incurred.
  The Registrant's certificate
  of incorporation and bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware
  General Corporation Law.
  Section 102(b)(7) of the Delaware
  General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall
  not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except
  for liability for any:
  ●
  transaction from which the director derives an improper personal benefit;
  ●
  act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
  ●
  unlawful payment of dividends or redemption of shares; or
  ●
  breach of a director's duty of loyalty to the corporation or its stockholders.
  The Registrant's certificate
  of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding
  in advance of its final disposition shall be paid by the Registrant upon delivery to it of an undertaking, by or on behalf of such director
  or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be
  indemnified by the Registrant.
  Section 174 of the Delaware
  General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of
  dividends or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the
  unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered
  in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent
  director receives notice of the unlawful acts.
  II-
  2
  As permitted by the Delaware
  General Corporation Law, the Registrant has entered into indemnity agreements with each of its directors and executive officers, that
  require the Registrant to indemnify such persons against any and all costs and expenses (including attorneys', witness or other
  professional fees) actually and reasonably incurred by such persons in connection with any action, suit or proceeding (including derivative
  actions), whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was
  a director or officer or is or was acting or serving as an officer, director, employee or agent of the Registrant or any of its affiliated
  enterprises. Under these agreements, the Registrant is not required to provide indemnification for certain matters, including:
  ●
  indemnification beyond that permitted by the Delaware General Corporation Law;
  ●
  indemnification for any proceeding with respect to the unlawful payment of remuneration to the director or officer;
  ●
  indemnification for certain proceedings involving a final judgment that the director or officer is required to disgorge profits from the purchase or sale of the Registrant's stock;
  ●
  indemnification for proceedings involving a final judgment that the director's or officer's conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct or a breach of his or her duty of loyalty, but only to the extent of such specific determination;
  ●
  indemnification for proceedings or claims brought by an officer or director against us or any of the Registrant's directors, officers, employees or agents, except for claims to establish a right of indemnification or proceedings or claims approved by the Registrant's board of directors or required by law;
  ●
  indemnification for settlements the director or officer enters into without the Registrant's consent; or
  ●
  indemnification in violation of any undertaking required by the Securities Act or in any registration statement filed by the Registrant.
  The indemnification agreements
  also set forth certain procedures that will apply in the event of a claim for indemnification thereunder.
  The Registrant has an insurance
  policy in place that covers its officers and directors with respect to certain liabilities, including liabilities arising under the Securities
  Act or otherwise.
  Item 7. Exemption from Registration Claimed.
  Not applicable.
  II-
  3
  Item 8. Exhibits.
  EXHIBIT
  INDEX
  Exhibit No.
  Description
  3.1
  Certificate of Incorporation of Adial Pharmaceuticals, Inc. (1)
  3.2
  Certificate of Amendment to Certificate of Incorporation of Adial Pharmaceuticals, Inc. (2)
  3.3
  Amended and Restated Bylaws of Adial Pharmaceuticals, Inc. (3)
  4.1
  Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (4)
  4.2
  Amendment No. 1 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (5)
  4.3
  Form of Stock Option Grant Notice, Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) and Notice of Exercise under the 2017 Equity Incentive Plan (6)
  4.4
  Amendment No. 2 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (7)
  4.5
  Amendment No. 3 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (8)
  4.6
  Amendment No. 4 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (9)
  4.7
  Amendment No. 5 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (10)
  4.8
  Amendment No. 6 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (11)
  5.1
  Opinion of Blank Rome LLP (12)
  23.1
  Consent of Marcum, LLP, Independent Registered Public Accounting Firm (12)
  23.2
  Consent of Blank Rome LLP (contained in Exhibit 5.1) (12)
  24.1
  Power of Attorney (included on the signature page of this registration statement) (12)
  107
  Filing Fee Table (12)
  (1)
  Incorporated by reference to the Registrant's Form S-1, as amended (File No. 333-220368), filed with the Securities and Exchange Commission on October 25, 2017.
  (2)
  Incorporated by reference to the Registrant's Form 8-K (File No. 001-38323) filed with the Securities and Exchange Commission on August 4, 2023.
  (3)
  Incorporated by reference to the Registrant's Annual Report on Form 10-K (File No.
  001-38323
  ) filed with the Securities and Exchange Commission March 28, 2022.
  (4)
  Incorporated by reference to the Registrant's Form S-8 (File No. 333-226884) filed with the Securities and Exchange Commission on August 16, 2018.
  (5)
  Incorporated by reference to the Registrant's Form S-8 (File No. 333-233760) filed with the Securities and Exchange Commission September 13, 2019.
  (6)
  Incorporated by reference to the Registrant's Form S-1, as amended (File No. 333-220368), filed with the Securities and Exchange Commission on September 7, 2017.
  (7)
  Incorporated by reference to the Registrant's Form S-8 (File No. 333-248759) filed with the Securities and Exchange Commission September 11, 2020.
  (8)
  Incorporated by reference to the Registrant's Current Report on Form 8-K (File No.
  001-38323
  ) filed with the Securities and Exchange Commission September 29, 2021.
  (9)
  Incorporated by reference to the Registrant's Current Report on Form 8-K (File No.
  001-38323
  ) filed with the Securities and Exchange Commission October 13, 2022.
  (10)
  Incorporated by reference to the Registrant's Current
  Report on Form 8-K (File No. 001-38323) filed with the Securities and Exchange Commission November 6, 2023.
  (11)
  Incorporated by reference to the Registrant's Current
  Report on Form 8-K (File No. 001-38323) filed with the Securities and Exchange Commission November 12, 2024.
  (12)
  Filed herewith.
  II-
  4
  Item 9. Undertakings.
  (a) The Registrant hereby
  undertakes:
  (1)
  To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  To include any prospectus required by Section 10(a)(3) of the Securities Act.
  (ii)
  To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
  Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
  offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
  may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
  and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration
  Fee" table in the Registration Statement.
  (iii)
  To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or
  any material change to such information in the registration statement.
  Provided, however
  ,
  that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment
  by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or
  Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.
  (2)
  That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
  a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
  to be the initial bona fide offering thereof.
  (3)
  To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.
  (b) The undersigned registrant
  hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual
  report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit
  plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement
  shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
  that time shall be deemed to be the initial bona fide offering thereof.
  (h) Insofar as indemnification
  for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
  to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification
  is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
  person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
  settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
  public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  II-
  5
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in Charlottesville, Virginia, on the 12
  th
  day of December, 2024.
  ADIAL PHARMACEUTICALS, INC.
  By:
  /s/ Cary J. Claiborne
  Name:
  Cary J. Claiborne
  Title:
  President and Chief Executive Officer
  POWER OF ATTORNEY
  Each of the undersigned, whose
  signature appears below, hereby constitutes and appoints each of Cary J. Claiborne and Vinay Shah, act singly, as his true and lawful
  attorney-in-fact and agent, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all
  capacities, to sign any or all amendments to this Registration Statement, whether pre-effective or post-effective, and to file the same
  with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
  attorney-in-fact and agent, or his substitute full power and authority to do and perform each and every act and thing necessary or appropriate
  to be done with respect to this Registration Statement or any amendments hereto in the premises, as fully to all intents and purposes
  as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes,
  or any of them, may lawfully do or cause to be done by virtue thereof.
  Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the
  date indicated.
  Signature
  Title
  Date
  /s/ Cary J. Claiborne
  President and Chief Executive Officer and Member of the
  December 12, 2024
  Cary J. Claiborne
  Board of Directors
  (Principal Executive Officer)
  /s/ Vinay Shah
  Chief Financial Officer
  December 12, 2024
  Vinay Shah
  (Principal Financial and Accounting Officer)
  /s/ J. Kermit Anderson
  Member of the Board of Directors
  December 12, 2024
  J. Kermit Anderson
  /s/ Robertson H. Gilliland
  Member of the Board of Directors
  December 12, 2024
  Robertson H. Gilliland
  /s/ Tony Goodman
  Member of the Board of Directors
  December 12, 2024
  Tony Goodman
  /s/ James W. Newman, Jr.
  Member of the Board of Directors
  December 12, 2024
  James W. Newman, Jr.
  /s/ Kevin Schuyler, CFA
  Chairman of the Board of Directors
  December 12, 2024
  Kevin Schuyler, CFA
  II-6